Search Results

You are looking at 1 - 10 of 114 items for :

  • immune-related adverse effects x
Clear All
Free access

Priscilla Cukier, Fernando C Santini, Mariana Scaranti and Ana O Hoff

. Conclusion Given the breadth of the emerging immunotherapy field, clinicians should be aware of the unique set of drug-related adverse effects, now known as immune-related adverse events (irAE). Predicting and understanding the aforementioned toxicity will

Open access

F Castinetti, F Albarel, F Archambeaud, J Bertherat, B Bouillet, P Buffier, C Briet, B Cariou, Ph Caron, O Chabre, Ph Chanson, C Cortet, C Do Cao, D Drui, M Haissaguerre, S Hescot, F Illouz, E Kuhn, N Lahlou, E Merlen, V Raverot, S Smati, B Verges and F Borson-Chazot

T Yedinak CG Alumkal J Fleseriu M 2010 Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes . Pituitary 13 29 – 38 . ( https://doi.org/10.1007/s11102

Free access

Joanne Y Y Ngeow and Laura S Ward

of immune-related adverse effects. Clinical options for managing immune-related complications remain limited. They are currently treated with steroids and immunosuppressants, just as classical autoimmune and inflammatory diseases are, but with far

Free access

Lucas Leite Cunha, Marjory Alana Marcello, Vinicius Rocha-Santos and Laura Sterian Ward

types, independent of the origin of cancer. The cost of enhancing the immune response is mirrored in adverse events, which are largely related to immune-mediated destruction of healthy tissues and uncontrolled inflammation. Endocrine malignancies are a

Free access

Lucas Leite Cunha, Marjory Alana Marcello and Laura Sterian Ward

to be related to tumor antigenicity. In fact, a correlation between protein expression profile and immune cell infiltration in DTC was observed ( Bruland et al . 2009 ). Some researchers have suggested that the expression of MUC1, NIS (SLC5A5), ATM

Free access

S Latteyer, V Tiedje, B Schilling and D Führer

– 660 . Dillard T Yedinak CG Alumkal J Fleseriu M 2010 Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes . Pituitary 13 29 – 38 . ( doi:10

Open access

Andrew M K Law, Elgene Lim, Christopher J Ormandy and David Gallego-Ortega

during breast cancer progression. In this review, we discuss the importance of the immune system during normal mammary gland development and the therapeutic strategies to target the two inter-related immune layers that operate in tumours; the adaptive

Free access

L A Emens, R T Reilly and E M Jaffee

can either overcome or circumvent intrinsic mechanisms of resistance to standard therapies. Manipulating the immune system to recognize and eradicate breast tumor cells is a highly attractive alternative approach to disease management. Passive

Free access

Mabel Ryder, Margaret Callahan, Michael A Postow, Jedd Wolchok and James A Fagin

-based toxicities, termed immune-related adverse events (irAEs), has emerged. Among these, endocrine irAEs are perhaps the least recognized but among the most highly symptomatic irAEs to occur following ipilimumab therapy ( Blansfield et al . 2005 , Dillard et al

Free access

Robert C Mould, Jacob P van Vloten, Amanda W K AuYeung, Khalil Karimi and Byram W Bridle

adverse events such as osteoporosis ( Wang et al. 2015 a ). Currently, there is a body of literature highlighting immunological effects of non-cancer-related hypo- and hyper-thyroidism. A separate set of studies evaluating the neuroendocrine-immune axis